Rituximab plus cladribine versus R-CHOP in frontline management of marginal zone lymphoma in China: a propensity-score matched multicenter study

医学 美罗华 内科学 切碎 胃肠病学 长春新碱 发热性中性粒细胞减少症 国际预后指标 中性粒细胞减少症 弥漫性大B细胞淋巴瘤 淋巴瘤 外科 环磷酰胺 化疗
作者
Yawen Wang,Jiadai Xu,Jing Li,Zheng Wei,Miaojie Shi,Rong Tao,Bobin Chen,Yuzhou Tian,Wenhao Zhang,Yan Ma,Lin Sun,Yiling Hou,Qilin Zhan,Jigang Wang,Xue Hou,Peng Liu
出处
期刊:Annals of Hematology [Springer Nature]
卷期号:101 (10): 2139-2148
标识
DOI:10.1007/s00277-022-04919-3
摘要

Marginal zone lymphoma (MZL) is an uncommon subtype of non-Hodgkin lymphoma (NHL). Combination of rituximab and cladribine (R-2CdA) is a potential option for indolent NHL (iNHL) and mantle cell lymphoma (MCL) patients. The goal of this multicenter retrospective study was to assess the efficacy and safety of R-2CdA in MZL to support consensus-reaching in first-line therapy in advanced-stage patients. We searched electronic medical records databases of eight centers in China. Between November 2014 and December 2019, 183 symptomatic advanced MZL patients (42 treated with R-2CdA and 141 with rituximab plus cyclophosphamide, adriamycin, vincristine, and prednisone [R-CHOP]) were identified. After propensity score matching (PSM) (1:1) to adjust for clinical characteristics, 39 patients from each treatment arm were selected. The overall response rate (ORR) (84.6% vs. 94.9%, P = 0.263) and complete response rate (59.0% vs. 66.7%, P = 0.487) were comparable between two protocols. Neither progression-free survival (PFS), including the 5-year PFS (67.7% vs. 56.1%, P = 0.352), nor overall survival was improved by R-2CdA versus R-CHOP. However, R-2CdA was more tolerable than R-CHOP in MZL patients regarding grade 3/4 hematological adverse events (odds ratio [OR] 0.565, 95% confidence interval [CI] neutropenic fever (OR 0.795, 95% CI 0.678-0.932), and infections (OR 0.800, 95% CI 0.640-1.000). Overall, our study demonstrated that R-2CdA is potentially as effective as but safer than R-CHOP in advanced MZL.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
陶醉水云发布了新的文献求助10
刚刚
daxia9527完成签到,获得积分10
2秒前
我是老大应助tanjuan采纳,获得10
3秒前
逗号发布了新的文献求助10
4秒前
迟大猫应助辉hui采纳,获得10
6秒前
Yolo完成签到,获得积分10
8秒前
咎谷槐完成签到,获得积分20
8秒前
T拐拐发布了新的文献求助20
8秒前
高灿完成签到 ,获得积分10
9秒前
haixuWang完成签到,获得积分10
10秒前
11秒前
刘荻萩应助科研通管家采纳,获得10
13秒前
科研通AI5应助科研通管家采纳,获得10
13秒前
13秒前
Owen应助科研通管家采纳,获得10
13秒前
无花果应助科研通管家采纳,获得10
13秒前
13秒前
脑洞疼应助科研通管家采纳,获得10
13秒前
科研通AI5应助科研通管家采纳,获得10
13秒前
英姑应助科研通管家采纳,获得10
13秒前
科研通AI5应助科研通管家采纳,获得30
13秒前
tanjuan发布了新的文献求助10
16秒前
小马甲应助幸福大白采纳,获得10
17秒前
科研通AI5应助幸福大白采纳,获得10
17秒前
科研通AI5应助幸福大白采纳,获得10
17秒前
17秒前
senli2018发布了新的文献求助10
18秒前
科研通AI5应助下点皮皮肠采纳,获得10
21秒前
Hahahahahahah发布了新的文献求助10
22秒前
科研通AI5应助ShiYanYang采纳,获得10
22秒前
T拐拐完成签到,获得积分20
22秒前
隐形曼青应助senli2018采纳,获得10
23秒前
24秒前
醉玉颓山完成签到,获得积分10
25秒前
26秒前
不去明知山完成签到 ,获得积分10
26秒前
27秒前
研友_VZG7GZ应助陶醉水云采纳,获得10
27秒前
28秒前
科研通AI5应助寒月如雪采纳,获得10
30秒前
高分求助中
Continuum Thermodynamics and Material Modelling 3000
Production Logging: Theoretical and Interpretive Elements 2700
Les Mantodea de Guyane Insecta, Polyneoptera 1000
Structural Load Modelling and Combination for Performance and Safety Evaluation 1000
Conference Record, IAS Annual Meeting 1977 820
England and the Discovery of America, 1481-1620 600
電気学会論文誌D(産業応用部門誌), 141 巻, 11 号 510
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 量子力学 光电子学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3572474
求助须知:如何正确求助?哪些是违规求助? 3142633
关于积分的说明 9448405
捐赠科研通 2844063
什么是DOI,文献DOI怎么找? 1563169
邀请新用户注册赠送积分活动 731661
科研通“疑难数据库(出版商)”最低求助积分说明 718667